In the past, we considered multiple myeloma the poor sibling among lymphoid malignancies. We have seen an amazing amount of change in this field, and Dr. Anderson and colleagues have contributed to that progress. But despite the progress, most patients still relapse,” noted Andrew D. Zelenetz, MD, PhD, Vice Chair of Informatics in the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, and Chair of the NCCN Congress on Hematologic Malignancies.

“Dr. Anderson gave a great overview of current and future strategies that may pan out to improve outcomes in multiple myeloma,” he noted at the NCCN Annual Congress. ■

Disclosure: Dr. Zelenetz reported no potential conflicts of interest.